We are pleased to announce that the closing procedures for the "Acquisition of a Newly Established Company that will succeed JSR's in vitro diagnostic pharmaceutical business," which we announced on April 22, 2025, were completed as scheduled today, October 1, 2025.
In conjunction with the subsidiary acquisition, the name of the Newly Established Company has been changed to Tokuyama Life Science Corporation.

For details, please see below.

(Update of the Previous Announcement)Notice Concerning the Acquisition of a Newly Established Company that will succeed JSR's in vitro diagnostic pharmaceutical business

(Reference) Press release dated April 22, 2025

Notice Concerning the Acquisition of a Newly Established Company that will succeed JSR's in vitro diagnostic pharmaceutical business

Notice Concerning the Acquisition of a Newly Established Company that will succeed JSR’s in vitro diagnostic pharmaceutical business (Presentation)

Q&A